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Abstract
CDKN2A is a proven and validated biomarker of ageing which acts as an off switch for cell proliferation. We have
demonstrated previously that CDKN2A is the most robust and the strongest pre-transplant predictor of post- transplant
serum creatinine when compared to ‘‘Gold Standard’’ clinical factors, such as cold ischaemic time and donor chronological
age. This report shows that CDKN2A is better than telomere length, the most celebrated biomarker of ageing, as a predictor
of post-transplant renal function. It also shows that CDKN2A is as strong a determinant of post-transplant organ function
when compared to extended criteria (ECD) kidneys. A multivariate analysis model was able to predict up to 27.1% of eGFR
at one year post-transplant (p = 0.008). Significantly, CDKN2A was also able to strongly predict delayed graft function. A pre-
transplant donor risk classification system based on CDKN2A and ECD criteria is shown to be feasible and commendable for
implementation in the near future.
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Introduction
Kidney transplantation is the optimum treatment for renal
failure but is restricted by donor shortage. A large proportion of
End Stage Renal Failure (ESRF) patients must therefore receive
alternative replacement therapies in the form of peritoneal dialysis,
or haemodialysis. Such treatment results in increasing morbidity
particularly affecting the cardiovascular system, a severely reduced
lifespan and poorer quality of life. ‘‘Extended Criteria Donor’’
(ECD) kidneys are increasingly used to meet this shortfall in kidney
supply.
In accordance with the Organ Procurement and Transplanta-
tion Network (OPTN) and United Network for Organ Sharing
(UNOS), an Expanded Criteria Donor (ECD) is one which is: [1].
a. 60 years or over
b. 50–59 years with at least 2 of the following three medical
criteria
i. Cerebro-Vascular Accident as the cause of death
ii. History of hypertension
iii. Pre retrieval creatinine more than 133 mmol/L
Although ECD organs incur elevated risks of Delayed Graft
Function (DGF) and ultimately have unfavorable long-term
outcomes compared with younger donor kidneys, average results
remain far superior to alternative treatment modalities, such as
haemodialysis. Some grafts, however, perform poorly – or never
function adequately – and thus display Primary Non Function
(PNF). The reasons for this phenomenon are unclear, but seem
likely to relate to the inability of older kidneys to tolerate and
recover from the multiple injurious processes associated with
transplantation. In essence, such organs will have more ‘miles on
the clock’ and thus not function as well, or last as long. The
presence of substantial cellular senescence will make them more
susceptible to the effects of transplant-related stresses. [2,3] In
general, however, poor function is difficult to predict as many
older organs perform adequately despite advanced chronological
age. [4,5] Dependent upon the numbers of senescent cells present
in an organ, tissue integrity may be impaired and the capacity to
withstand stress reduced. Furthermore, senescence-associated
upregulation of pro-inflammatory cytokine gene expression may
lead to chronic persistent inflammation. We have therefore
hypothesised that the biological age of the organ, rather than just
its chronological age, may have a major impact on allograft
function and that this may be directly relevant to discriminating
between ECD organs.
This would imply that the expression of genes involved in
cellular processes regulating biological ageing, should provide
suitable reporters for investigating such a hypothesis. Indeed,
robust and reproducible studies have shown that gene expression
of senescence markers in a donor organ (organ bioage), can predict
renal function in vivo, irrespective of classical parameters
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currently in use, such as donor chronological age and sub optimal
pre-retrieval serum creatinine [6,7].
To date, of those putative biomarkers of ageing (BoA) that have
been tested, very few meet the Baker and Sprott criteria required
for validation. [8] This dictates that a valid BoA must demonstrate
variation of sufficient magnitude in short-term longitudinal, or in
cross-sectional studies, to be of predictive value within a
population or cohort with regard to physiological capacity at a
later chronological age, in the absence of disease. [9] Failures
include Senescence Associated b Galactosidase (SA-b-GAL),
advanced glycation end products and lipofuscin, which were
originally supported by substantial in vitro evidence. [10] In vivo,
only two BoA have been validated with respect to renal function:
Cyclin Dependant Kinase 2A (CDKN2A) and telomere length
[6,7].
Telomeres are nucleo-protein complexes at the ends of
chromosomes with a DNA component comprising variable lengths
of a TTAGGG simple repeat. Their primary role includes
maintaining stability and protecting the integrity of chromosomes.
[11] In somatic cells telomeric DNA shortens in length as a
consequence of the end replication problem. [12] The rate of
telomere shortening is directly influenced by oxidative stress. [13]
This provides a rationale for using telomere length as a BoA at the
cellular level and potentially explains the impact of environmental
and lifestyle factors on inter-individual differences in the rate of
ageing, [14] though with the caveat that it acts as a proxy for the
effects of stress and not causal for it [15].
CDKN2A expression is a key age-related component of
senescence in human renal allografts and renal disease. [16,17]
CDKN2A expression is elevated as a function of increasing
cellular stress and organismal ageing. As such, this typically
accompanies the telomere shortening observed during normal
human ageing. CDKN2A acts as a tumour suppressor, is a
component of STASIS (stress and stimulation induced senescence)
[18] and is functionally involved in maintaining cells in a state of
growth arrest. It has previously been demonstrated to be a
significant pre-transplant predictor of post transplant renal
allograft function [6,7,19].
In this study, we have sought to directly compare the expression
of CDKN2A and telomere length in pre-implantation, time zero
biopsies and correlate this with renal function up to 1 year post-
operatively. We have sought to determine associations with donor
chronological age and other important clinical variables in both
univariate and multivariate regression analysis. Included in this
analysis was renal function, assessed using the 4 variable
‘‘Modification of Diet in Renal Disease Study Group’’ formula -
MDRD 4 eGFR (ml/min/1.73 m2), referred to as eGFR in the
subsequent text. These analyses were designed to provide a basic
indication of the importance of each respective BoA and to assess
their capacity pre-transplant to predict post-transplant function
and any associated adverse clinical characteristics, when used
either singly, or in combination. Any indication of suitability in this
respect could then be exploited, to provide a simple pre-transplant
scoring or classification system by assessing BoA expression in the
allograft as it is being cross-matched.
Results
Association between Biological Age and Chronological
Age
Prior to analysing the predictive power of biomarkers of ageing
on renal function, data were validated by determining the
association between telomere length and CDKN2A. A Pearson
correlation between the two revealed no statistical significance
(p = 0.87, n = 15). Telomere length and CDKN2A were then
separately correlated with donor chronological age. Telomere
length was shown to inversely correlate with chronological age
(p = 0.036, CC=20.242, Figure 1a), while CDKN2A levels
positively associated with increasing chronological age (p,0.001,
CC=0.597, Figure 1b). These findings indicate that CDKN2A is
more robustly associated with the chronological ageing process in
kidney tissue when compared to telomere length. There was no
difference in demographic and clinical data between both
CDKN2A and telomere groups (Table 1).
BoA and Correlation with Renal Function Post-Transplant
Pearson correlation showed a significant association between
shortening telomere length and deteriorating eGFR at 6 months
and at 1 year post-transplant (p = 0.038 & p= 0.041, Figure 2).
However, increasing levels of CDKN2A expression were associ-
ated with decreasing eGFR levels at 6 months and 1 year post-
transplant (p = 0.020 & p=0.012, Figure 3).
Univariate Linear Regression
Univariate linear regression was used in order to assess the
individual predictive power of multiple variables on eGFR. Each
variable was used to predict function at both 6 months (Table 2)
and 1 year (Table 3) post transplantation. The results indicated
that CDKN2A, ECD, and donor chronological age were the
strongest univariate predictors for eGFR. Telomere length in
contrast displayed a poorer predictive ability in general. As
expected, other clinical variables that are included in ECD criteria
(donor age, donor hypertension, death by CVA but not high
serum creatinine) significantly predicted eGFR at both timelines.
Interestingly, there was a small but significant association for
recipients who suffered any form of glomerulonephritis (GN)
resulting in end stage renal failure. Recipients with ESRF second
to GN displayed poorer renal function at both timelines (MWU - 6
months p= 0.05, 1 year p= 0.04). Important univariate associa-
tions displayed in Table 2 and 3 include:
6 months. Donor chronological age predicted 14.3% of the
variability in eGFR whilst ECD kidney category predicted 12.1%.
CDKN2A predicted 13.5% of the eGFR, whilst telomere length
predicted 7.9%.
1 year. Donor chronological age predicted 21.4% of the
eGFR whilst ECD kidney category predicted 17.4%. CDKN2A
predicted 16.6% of the eGFR, whilst telomere length remained at
7.9%.
Multivariate Linear Regression Analysis
A multivariate regression model encompassing the three
principle pre-transplant variables was formulated using eGFR as
the dependant variable. The covariates were based on CDKN2A
and the stronger clinical univariate predictors: ECD and presence
or absence of glomerulonephritis in the recipient. Since donor
hypertension, donor chronological age and death by CVA are
already included under ECD criteria, they were not included as
separate covariates in the model. The addition of telomere length
to any model severely weakened it’s associations with renal
function resulting in a statistically insignificant outcome. A total of
two models were formulated at 6 months and 1 year timelines with
a p-value of ,0.017 taken to be statistically significant using
Bonferroni’s correction. At 6 months, the model approached
statistical significance (p= 0.021) as outlined in Table 4. Statistical
significance was reached at 1 year where the model predicted
27.1% of the eGFR (Adjusted R2 0.271, n = 31, p = 0.008
ANOVA) with respective individual contributions outlined in
Table 5.
Pre-Transplant CDKN2A Predicts Renal Function
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CDKN2A, Delayed Graft Function and Rejection
Increased expression of CDKN2A in pre-implantation biopsies
was significantly associated with DGF (MWU, p= 0.032). Median
CDKN2A expression levels in patients with DGF were compared
with those grafts that showed primary function (DGF CDKN2A
mean expression = 2.61 (SD 0.56, n = 6) vs primary function
CDKN2A mean expression = 1.61 (SD 1.30, n= 27)). DGF in
itself was significantly correlated with graft rejection episodes
(Fisher’s exact test, n = 113, p = 0.001). This data suggests that
high levels of CDKN2A are linked to increased allograft
immunogenicity resulting in increased rejection episodes in the
long term and may also play a role in the aetiology of DGF
through a similar mechanism.
A total of 112 patients with rejection data were analysed. Biopsy
proven evidence of acute rejection was present in 25.0% (n= 28) of
the total. All such grafts were viable at 6 months with a median
eGFR of 39.05 ml/min/1.73 m2 (SD 17.16) however, there was 1
graft failure at 1 year, with a median eGFR for all other grafts
(n = 27) of 39.70 ml/min/1.73 m2 (SD18.09). There was no direct
statistical relationship between CDKN2A and rejection itself
(p = 0.741).
Discussion
We have demonstrated that the pre-transplant expression of two
independent BoAs correlates with renal function post-transplant.
Greater biological age, as determined by shorter telomere length,
or higher relative CDKN2A expression, correlated with poorer
post-transplant function [19]. This is in keeping with observations
in the field. Classically, organs from older donors show poorer
function post-transplant and have a decreased lifespan. Although
this holds true in most cases, there are times when such organs
perform very well and last beyond their life expectancy. Our
results indicate that such variation in organ function could be
attributed to the difference in biological age. Our data indicate
that pre-transplant CDKN2A expression is the strongest biomark-
er of renal function up to 1 year post-operatively. When used in
the context of Baker and Sprott’s criterion, CDKN2A appears to
be significantly more robust as a BoA than telomere length. The
latter may be viewed as an effective but imprecise BoA.
Distinguishing between age-related telomere attrition and dis-
ease-related attrition is difficult [8]. Using both together as a
composite measure, alongside chronological age, should be of
further benefit in this context. Clinical translation of this should be
Figure 1. Scatter plots showing the correlation between biomarkers of ageing and donor chronological age. a. Negative correlation
between Donor Chronological Age and Telomere Length. n = 43, CC:20.242, p = 0.036. b. Positive correlation between Donor Chronological Age and
CDKN2A. n = 33, CC: 0.597, p,0.001.
doi:10.1371/journal.pone.0068133.g001
Table 1. Demographic and important clinical parameters were compared between the separate CDKN2A group and the telomere
group.
CDKN2A n=33 Mean (SD) Telomere n=43 Mean (SD) p value
Donor Gender** (male/female) 15/18 20/23 0.589
Donor Age** 48.0 (15.7) 51.8 (15.51) 0.189
DCD/DBD organ* 4/29 9/34 0.677
Mismatch at all A,B,DR Loci* (yes/no) 8/25 10/33 0.607
Recipient Age** 50.6 (12.7) 49.7 (12.6) 0.344
Cold Ischaemic Time** 15.5 (3.9) 13.9 (4.0) 0.267
There were no significant differences between the two groups which would account for the different correlations with renal function (eGFR).
**Unpaired t-Test.
*Fisher’s exact test.
doi:10.1371/journal.pone.0068133.t001
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straightforward, as our methodology is readily adaptable to
implementation when the organ is undergoing cross-match.
In comparison to previous studies, we used the estimated
Glomerular Filtration Rate (eGFR) as a marker for renal function
as it is traditionally considered the best overall index of function in
health and disease. [20] The National Kidney Foundation now
recommends the MDRD 4 to estimate the GFR and better detect
early onset kidney disease. Although the eGFR is considered to be
the best overall index of renal function, it is relatively insensitive at
detecting early renal disease and does not correlate well with
tubular dysfunction [21,22].
We have previously shown that CDKN2A is stronger than
donor chronological age (DCA) at predicting post transplant
function when serum creatinine is used as the marker for renal
function. [7] However, when eGFR is used to measure renal
function, DCA seemed to have a better predictive power than
CDKN2A (Tables 2 and 3). Further univariate regression analysis
revealed that the predictive power of CDKN2A on eGFR was
almost equal to that of ECD kidney criteria (Tables 2 and 3). In
multivariate analysis, the only statistically significant contribution
to both models is CDKN2A, indicating it’s predictive superiority
in this limited cohort.
Despite increasing efforts by the transplant community to
increase the availability of donor organs, there remains a
significant shortfall with several thousand patients dying on the
waiting list each year. The introduction of ECD kidneys has
improved the quantitative discrepancy of such organs but we are
still a distance from achieving satisfactory targets. Novel
techniques of organ discrimination are therefore of huge
importance in this respect. With the standard incorporation of
biomarkers in assessing organ quality pre-operatively, it would
seem logical that transplantation would be safer and an increase in
Figure 2. Scatterplots showing the primary significant relationship between telomere length and renal function, as measured by
MDRD 4 eGFR at a) 6 months and b) 1 year. a. Telomere Length vs MDRD 4 eGFR at 6 months: n = 43, CC: 0.317, p = 0.038, b. Telomere Length
vs MDRD 4 eGFR at 1 year: n = 41, CC: 0.320, p = 0.041.
doi:10.1371/journal.pone.0068133.g002
Figure 3. Scatterplots showing the primary significant relationship between CDKN2A and renal function, as measured by MDRD
4 eGFR at a) 6 months and b) 1 year. a.CDKN2A vs MDRD 4 eGFR at 6 months. n = 33, CC: 20.403, p = 0.020. b.CDKN2A vs MDRD 4 eGFR at
1 year. n = 32, CC: 20.439, p = 0.012.
doi:10.1371/journal.pone.0068133.g003
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the number of kidney transplants would subsequently ensue.
CDKN2A is also related to DGF which in itself is associated with
poorer graft performance and decreased long term survival.
[23,24] The reason for this remains to be determined, but may
relate to biologically older organs being less tolerant to physical
stress and requiring more time to recover from peri-transplant
ischaemia reperfusion injury.
Why CDKN2A expression levels, in this study, have been
observed to be a stronger biomarker of ageing than telomere
length remains to be proven. Both fulfil the Baker and Sprott
criterion, but the weakness of telomere length in predicting
functional capacity in a solid organ is apparent. A contributory
factor may be the extent of inter individual variation in telomere
length at a given chronological age. [6,8,14] Our data are
consistent with those of Koppelstaetter et al [6], who previously
demonstrated that telomere length was inferior to CDKN2A in
determining variability on post-transplant serum creatinine levels
in renal allografts. Inter-individual variation in CDKN2A
expression at a given chronological age has not been fully
determined, though increased expression of CDKN2A at the
cellular level, remains a robust marker of a senescent state and its
elevated expression is coincident with a reduction in cellular
proliferation. [25] In essence, its expression may be viewed as an
‘off switch’ for the cell and hence the degree of inter-individual
variation observed with telomere length, is not expected to be as
great. Our observations have direct relevance for any future
strategies employing biomarkers of ageing either clinically, or
epidemiologically. Telomere length is currently used widely in this
context. We are now evaluating CDKN2A similarly, in large
epidemiological studies, to evaluate its robustness with greater
analytical power.
Based on current findings relating to the predictive power of
CDKN2A on eGFR, it would follow that a scoring system
incorporating biological markers would provide additional infor-
mation for patients and clinicians during the organ selection
process. Reference is made to larger studies such as the one in use
by the OPTN in the US for deceased donor kidneys based on ten
pre-transplant covariates, the Kidney Donor Risk Index. [26]
Undoubtedly, this novel scoring system adds a vital tool to the
allograft allocation process. Importantly however, it does not
include reference to biological age which may be viewed as an
essential parameter of modernised scoring systems. In addition, the
study itself showed similar results with age matching alone
allowing for the possibility of a simpler scoring technique with
equal efficacy. We therefore propose a 4 tier categorical scoring
system based on biological age of the graft and ECD. Allografts are
classified Category I to Category IV based on a straight forward
assessment outlined below, with Category I allografts predicting
better performance than Category 4 (Table 6).
The mean value for CDKN2A gene expression (1.8) was used as
the cut-off value in the scoring system. Moreover, it can be seen
from the scatter plots of CKDN2A vs eGFR at 1 year that renal
function deteriorates significantly at CDKN2A expression levels
above 1.8. ECD kidneys occupy both category III and category IV
Table 2. Univariate linear regression analysis showing the
predictive power of CDKN2A, telomere length and other
relevant clinical variables on renal function at 6 months.
Variable MDRD 4 eGFR at 6 months
n Adjusted R2 p-value
CDKN2A expression 33 0.135 0.020
Telomere Length 43 0.079 0.038
Donor Chronological Age 120 0.143 ,0.001
GN in recipient 112 0.029 0.040
ECD Kidney 118 0.121 ,0.001
Donor Hypertension 107 0.051 0.011
CVA in Donor 111 0.057 0.007
Donor pre-retrieval Creatinine
.133 mMol/L
110 20.008 ns
Mismatch at A, B and DR Loci 114 20.009 ns
Previous Transplant 120 0.000 ns
Cold Ischaemic Time 114 0.019 ns
Donor Sex 120 20.001 ns
DCD/DBD 63 20.003 ns
Note the superior predictive strength of CDKN2A when compared to telomere
length. (GN: Glomerulonephritis, DCD: Donation after Cardiac Death, DBD:
Donation after Brain Death, CVA: Cerebro Vascular Accident, ECD: Extended
Criteria Donor).
doi:10.1371/journal.pone.0068133.t002
Table 3. Univariate linear regression analysis showing the
predictive power of CDKN2A, telomere length and other
relevant clinical variables on renal function at 1 year.
Variable MDRD 4 eGFR at 1 year
n Adjusted R2 p-value
CDKN2A expression 32 0.166 0.012
Telomere Length 41 0.079 0.041
Donor Chronological Age 104 0.214 ,0.001
GN in recipient 105 0.028 0.048
ECD Kidney 103 0.174 ,0.001
Donor Hypertension 100 0.069 0.005
CVA in Donor 95 0.075 0.004
Donor pre-retrieval Creatinine
.133 mMol/L
95 20.011 ns
Mismatch at A, B and DR Loci 98 20.010 ns
Previous Transplant 104 0.000 ns
Cold Ischaemic Time 98 0.014 ns
Donor Sex 105 20.009 ns
DCD/DBD 49 0.001 ns
Note again the superiority of CDKN2A over telomere length in particular. (GN:
Glomerulonephritis, DCD: Donation after Cardiac Death.
DBD: Donation after Brain Death, CVA: Cerebro Vascular Accident, ECD:
Extended Criteria Donor).
doi:10.1371/journal.pone.0068133.t003
Table 4. Multivariate model outcome for eGFR at 6 months.
Independent Variable
Standardised
Coefficients (Beta) p-value
CDKN2A 20.397 0.034
ECD Kidney 20.211 0.233
Recipient
Glomerulonephritis
20.293 0.088
The model approaches statistical significance using the strict Bonferroni
correction (p = 0.021).
doi:10.1371/journal.pone.0068133.t004
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in this pre-transplant scoring tool meaning that ECD status carries
a poorer prognosis than CDKN2A itself. The allocation of
CDKN2A to a higher tier in this scoring system would require
further studies to strengthen the correlations observed above.
Since DCA forms part of ECD criteria, it was not used as a single
determinant of transplant function in multivariate analysis or the
categorical scoring system.
A further benefit from our data, is that strategies to mitigate the
rate of biological ageing applied to living donors would be
expected to have impact on post-transplant outcomes. Reduction
of psychological and psychosocial stress and improved lifestyle via
changes to diet and exercising might readily be considered.
[14,27,28] Biomarkers, specifically CDKN2A, may well expand
the field of octogenarian donation for example, by discriminating
organs with ‘‘less miles on the clock’’. Larger multicentre studies
are needed to strengthen the hypothesis and the proposed scoring
system suggested in this report. It is envisaged that the biomarker
CDKN2A will be integrated into a similar, robust and validated
pre-transplant scoring system for all kidneys and other transplant-
ed organs in the near future.
Methods
Ethics
This is an ongoing prospective study which has been approved
by the Regional Ethics Committee of the North Glasgow NHS
Trust. Donors from the national pool donated their organs for
transplantation. The recipient of the organ provided pre-operative
written informed consent for tissue analysis and scientific research.
Samples were anonymised and subsequently analyzed.
Study Population
The global study population is representative of the national
UK deceased donor pool. A total of 120 transplant patients were
included which were performed in the Western Infirmary,
Glasgow between March 2008 and February 2011. All transplants
were followed up for post-operative clinical data. Telomere length
was calculated for 43 transplanted kidneys. A separate group
(n = 33) yielded CDKN2A expression. There were 15 matched
samples as a result of small biopsy specimens allowing RNA or
DNA to be obtained separately and not together. Table 1 shows
the demographic data for the CDKN2A and telomere groups.
Patients, in whom genetic data was not available, were included in
the global cohort for clinical analysis. The primary cause of end
stage renal disease (ESRF) in the recipients was Adult Polycystic
Kidney Disease (APKD) followed by chronic pyelonephritis/reflux
disease, hypertensive nephropathy, IgA nephropathy and the
glomerulonephritides. The immunosuppressive regimen consisted
primarily of basiliximab at induction and day 4 with a
maintenance regime consisting of tacrolimus, mycophenolate
mofetil and prednisolone.
Human Renal Biopsies and RNA/DNA Extraction
Renal biopsies were obtained on the surgical backbench via
wedge resection or needle biopsy according to the surgeon’s
preference. All biopsies were obtained from ‘‘donation after brain
death’’ (DBD) and ‘‘donation after cardiac death’’ (DCD) donors.
All samples were stored in ‘RNA later’ solution (Ambion, Austin,
TX, USA) at –20uC until processing. RNA was extracted using
Trizol reagent (Invitrogen, Paisley, UK) following manufacturer’s
guidelines. The MaxwellH 16 DNA purification robot kits by
Promega were used for for DNA isolation.
Delayed Graft Function (DGF)
DGF was defined as failure of serum creatinine to fall by half
within seven days of the transplant, or need for dialysis within
seven days of the transplant, except dialysis performed for fluid
overload or elevated serum potassium levels [29].
MDRD 4 eGFR
The final value for the eGFR was calculated electronically by a
biochemical and clinical database – SERPR. The four variables
used in the equation include serum creatinine, age, race and
gender [20].
CDKN2A Expression Determination
Relative quantitative real-time PCR (qRT-PCR) was used to
estimate mRNA levels corresponding to the candidate senescence
associated gene (SAGs) - CDKN2A. Expression levels were
measured against a reference HPRT housekeeping gene on an
ABI PrismH 7700 Sequence Detection System. Sequences of
human TaqManTM Primer/Probe sets designed by Primer
Express algorithm (Applied Biosystems, Austin, TX, USA).
HPRT
Forward Primer (5/2CTTGCTCGAGATGTGATGAAG-3/
),
Reverse Primer (5/2CAGCAGGTCAGCAAAGAATTTA-
TAG-3/),
Probe (5/2FAM-ATCACATTGTAGCCCTCTGTGTGCT-
CAAGGTAMRA-3/)
CDKN2A
Forward Primer (5/2CATAGATGCCGCGGAAGG-3/),
Reverse Primer (5/2CCCGAGGTTTCTCAGAGC-3/),
Probe (5/2FAM-CCTCAGACATCCCCGATTG-TAMRA-
3/)
The comparative threshold cycle method (DDCT) was em-
ployed as the method of choice to quantify relative gene
expression. The quantification result was transformed to an
Table 5. Multivariate model outcome for eGFR at 1 year.
Independent Variable
Standardised
Coefficients (Beta) p-value
CDKN2A 20.428 0.019
ECD Kidney 20.236 0.166
Recipient
Glomerulonephritis
20.311 0.061
The model explains 27.1% of the eGFR p = 0.008.
doi:10.1371/journal.pone.0068133.t005
Table 6. Suggested Donor Kidney Classification system
incorporating CDKN2A as the biomarker of ageing and ECD
kidney criteria.
Category I SCD Kidney and CDKN2A expression levels ,1.8
Category II SCD Kidney and CDKN2A expression levels .1.8
Category III ECD Kidney and CDKN2A expression levels ,1.8
Category IV ECD Kidney and CDKN2A expression levels .1.8
(SCD – Standard Criteria Donors, ECD – Extended Criteria Donors). Predicted
kidney function and incidence of graft failure increases with higher category
placement.
doi:10.1371/journal.pone.0068133.t006
Pre-Transplant CDKN2A Predicts Renal Function
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exponential value, 2–DDCt [30] where Ct is the threshold cycle, or
the cycle when the product was first detected. Before undertaking
this quantitative study we demonstrated that the efficiency of
amplification of reference (HPRT) and test genes were approxi-
mately equal (data not shown).
Telomere Length Determination
Telomere length determination was performed by qPCR using
a Roche Light Cycler LC480. Telomere length analyses were
performed in triplicate for each sample, using a single-copy gene
amplicon primer set (acidic ribosomal phosphoprotein, 36B4) and
a telomere-specific amplicon primer set. Quality control param-
eters employed for the amplifications comprised using a cut off
0.15 for the standard deviation (SD) of the threshold cycle (Ct) for
sample replicates. At a SD above 0.15 the sample was reanalysed.
The average SD across plates was ,0.05.
Relative telomere length was estimated from Ct scores using the
comparative Ct method after confirming that the telomere and
control gene assays yielded similar amplification efficiencies. This
method determines the ratio of telomere repeat copy number to
single copy gene number (T/S) ratio in experimental samples
relative to a control sample DNA. This normalised T/S ratio was
used as the estimate of relative telomere length (Relative T/S).
TELOMERE
Telo 1 Sequence (59 to 39)
CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG
GTT TGG GTT
Telo 2 Sequence (59 to 39)
GGC TTG CCT TAC CCT TAC CCT TAC CCT TAC
CCT TAC CCT
36B4
36B4d Sequence (59 to 39)
CCC ATT CTA TCA TCA ACG GGT ACA A
36b4u Sequence (59 to 39)
CAG CAA GTG GGA AGG TGT AAT CC
Statistics
Data analyses were performed using SPSS statistical package
version 17. The adjusted R2 was used to indicate the extent to
which the dependant variable (eGFR) is explained by the
independent variable in question. The association was deemed
to be statistically significant if the p value ,0.05. Prior to
multivariate regression, preliminary analysis was conducted to
ensure no violation of the assumptions of normality, linearity and
multicollinearity. Any missing values were removed by pairwise
deletion. Bonferroni’s adjustment was used to calculate the exact p
value for the multivariate models.
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